Indus Genetic Profile
Key Indicators
- Authorised Capital ₹ 5.00 M
- Paid Up Capital ₹ 4.90 M
- Company Age 22 Year, 3 Months
- Last Filing with ROC 31 Mar 2010
- Open Charges ₹ 1.00 Cr
- Satisfied Charges ₹ 1.60 M
About Indus Genetic
Indus Genetic Private Limited (IGPL) is a Private Limited Indian Non-Government Company incorporated in India on 08 November 2002 and has a history of 22 years and three months. Its registered office is in Ut, Chandigarh.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2010. It's a company limited by shares with an authorized capital of Rs 5.00 M and a paid-up capital of Rs 4.90 M.
The company currently has active open charges totaling ₹1.00 Cr. The company has closed loans amounting to ₹1.60 M, as per Ministry of Corporate Affairs (MCA) records.
Harpreet Kaur, Raghbir Singh, and Sukhjeet Singh serve as directors at the Company.
Company Details
- Location Ut, Chandigarh
-
Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
Social Media
-
Corporate Identity Details
-
CIN/LLPIN
U24232CH2002PTC025551
-
Company No.
025551
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
08 Nov 2002
-
Date of AGM
30 Sep 2010
-
Date of Balance Sheet
31 Mar 2010
-
Listing Status
Unlisted
-
ROC Code
Roc Chandigarh
Industry
Who are the key members and board of directors at Indus Genetic?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Harpreet Kaur
|
Director | 08-Nov-2002 | Current |
|
Raghbir Singh
|
Director | 08-Nov-2002 | Current |
|
Sukhjeet Singh
|
Director | 08-Nov-2002 | Current |
Financial Performance of Indus Genetic.
Enhance accessibility to Indus Genetic's financial data by unlocking access to both Standalone and Consolidated balance sheets, Profit & Loss Statements, Ratios, Related Party Transactions, and additional relevant information.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Indus Genetic?
Unlock access to Indus Genetic's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Charges (Loans)
₹10.00 M
₹1.60 M
Charges Breakdown by Lending Institutions
- Bank Of India : 0.50 Cr
- Small Industries Development Bank Of India : 0.50 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 31 Dec 2004 | Bank Of India | ₹5.00 M | Open |
| 31 Dec 2004 | Small Industries Development Bank Of India | ₹5.00 M | Open |
| 29 Jun 2006 | Indian Overseas Bank | ₹1.60 M | Satisfied |
How Many Employees Work at Indus Genetic?
Unlock and access historical data on people associated with Indus Genetic, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Indus Genetic, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Indus Genetic's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.